H.C. Wainwright assumed coverage of SAB Biotherapeutics (SABS) with a Buy rating and $10 price target Following a positive topline data readout in healthy volunteers that showcased sustained immunomodulation and a clean safety profile, SAB’s human anti-thymocyte immunoglobulin, SAB-142, is positioning itself as a potential new immunotherapy to prevent and control the progression of type 1 diabetes, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAB Biotherapeutics reports Q1 net loss $5.2M vs $5M last year
- SAB Biotherapeutics Reports 2024 Financial Results and Advances T1D Therapy
- SAB Biotherapeutics price target lowered to $20 from $25 at Chardan
- Promising Outlook for SAB Biotherapeutics’ SAB-142: Positive Phase 1 Results and Future Growth Potential Justify Buy Rating
- SAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024